BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23074200)

  • 1. Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas.
    Alentorn A; Marie Y; Carpentier C; Boisselier B; Giry M; Labussière M; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Idbaih A
    Neuro Oncol; 2012 Nov; 14(11):1393-403. PubMed ID: 23074200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas.
    Martinho O; Longatto-Filho A; Lambros MB; Martins A; Pinheiro C; Silva A; Pardal F; Amorim J; Mackay A; Milanezi F; Tamber N; Fenwick K; Ashworth A; Reis-Filho JS; Lopes JM; Reis RM
    Br J Cancer; 2009 Sep; 101(6):973-82. PubMed ID: 19707201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.
    Koschmann C; Zamler D; MacKay A; Robinson D; Wu YM; Doherty R; Marini B; Tran D; Garton H; Muraszko K; Robertson P; Leonard M; Zhao L; Bixby D; Peterson L; Camelo-Piragua S; Jones C; Mody R; Lowenstein PR; Castro MG
    Oncotarget; 2016 Oct; 7(40):65696-65706. PubMed ID: 27582545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Better prognosis of patients with glioma expressing FGF2-dependent PDGFRA irrespective of morphological diagnosis.
    Chen D; Persson A; Sun Y; Salford LG; Nord DG; Englund E; Jiang T; Fan X
    PLoS One; 2013; 8(4):e61556. PubMed ID: 23630597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.
    Puputti M; Tynninen O; Sihto H; Blom T; Mäenpää H; Isola J; Paetau A; Joensuu H; Nupponen NN
    Mol Cancer Res; 2006 Dec; 4(12):927-34. PubMed ID: 17189383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features.
    Smith JS; Wang XY; Qian J; Hosek SM; Scheithauer BW; Jenkins RB; James CD
    J Neuropathol Exp Neurol; 2000 Jun; 59(6):495-503. PubMed ID: 10850862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDGFRA gain in low-grade diffuse gliomas.
    Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Nonoguchi N; Pierscianek D; Kim YH; Mariani L; Vital A; Perry A; Ohgaki H
    J Neuropathol Exp Neurol; 2013 Jan; 72(1):61-6. PubMed ID: 23242283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High CHI3L1 expression is associated with glioma patient survival.
    Steponaitis G; Skiriutė D; Kazlauskas A; Golubickaitė I; Stakaitis R; Tamašauskas A; Vaitkienė P
    Diagn Pathol; 2016 Apr; 11():42. PubMed ID: 27121858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas.
    Paugh BS; Zhu X; Qu C; Endersby R; Diaz AK; Zhang J; Bax DA; Carvalho D; Reis RM; Onar-Thomas A; Broniscer A; Wetmore C; Zhang J; Jones C; Ellison DW; Baker SJ
    Cancer Res; 2013 Oct; 73(20):6219-29. PubMed ID: 23970477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-MET overexpression and amplification in gliomas.
    Kwak Y; Kim SI; Park CK; Paek SH; Lee ST; Park SH
    Int J Clin Exp Pathol; 2015; 8(11):14932-8. PubMed ID: 26823824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
    Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
    Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
    Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
    Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study.
    Nobusawa S; Stawski R; Kim YH; Nakazato Y; Ohgaki H
    Neuropathology; 2011 Dec; 31(6):583-8. PubMed ID: 21382095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
    Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
    J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of microRNA-504 is associated with poor prognosis in high-grade glioma.
    Guan Y; Chen L; Bao Y; Pang C; Cui R; Li G; Liu J; Wang Y
    Int J Clin Exp Pathol; 2015; 8(1):727-34. PubMed ID: 25755767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double minute amplification of mutant PDGF receptor α in a mouse glioma model.
    Zou H; Feng R; Huang Y; Tripodi J; Najfeld V; Tsankova NM; Jahanshahi M; Olson LE; Soriano P; Friedel RH
    Sci Rep; 2015 Feb; 5():8468. PubMed ID: 25683249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.